Semaglutide
Research Overview · Mechanism of Action · Reconstitution Guide
Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to native human GLP-1. It was engineered with a C18 fatty diacid chain attached via a linker to lysine at position 34, enabling strong albumin binding and extending its half-life to approximately 7 days. In research models, semaglutide activates GLP-1 receptors in the pancreas, hypothalamus, and gastrointestinal tract, producing downstream effects on insulin secretion, glucagon suppression, gastric emptying, and appetite-regulating neural circuits.
Mechanism of Action
GLP-1 receptor agonism stimulates adenylyl cyclase via Gs protein coupling, elevating intracellular cAMP. In pancreatic beta cells, this potentiates glucose-dependent insulin secretion. In hypothalamic arcuate nucleus neurons, GLP-1R activation suppresses NPY/AgRP orexigenic signaling and activates POMC/CART anorexigenic pathways. Semaglutide also slows gastric emptying through vagal afferent signaling, reducing postprandial glucose excursions. The fatty acid modification confers non-covalent albumin binding (>99% plasma protein bound), dramatically extending circulating half-life compared to native GLP-1 (2 minutes).
Key Studies & References
Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 384:989–1002. STEP 1 trial: 68-week RCT demonstrating 14.9% mean body weight reduction vs 2.4% placebo.
Marso SP et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. NEJM 375:1834–1844. SUSTAIN-6 trial: cardiovascular outcomes data.
Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism 27:740–756. Comprehensive mechanistic review.
Bacteriostatic Water Reconstitution Guide
Research Use Only — The following reconstitution information is provided for in vitro laboratory research purposes only. Not for human or veterinary use.
Recommended Solvent
Bacteriostatic water (0.9% benzyl alcohol)
Standard Volume
Add 2 mL bacteriostatic water to a 5 mg vial to yield a 2.5 mg/mL (2500 mcg/mL) solution.
Working Concentration
2.5 mg/mL (2500 mcg/mL) standard; may dilute further for lower-dose research protocols.
Storage (Reconstituted)
Reconstituted: 2–8°C, use within 28 days. Lyophilized: -20°C, desiccated.
Stability Window
Stable for 28 days at 2–8°C post-reconstitution. Avoid repeated freeze-thaw cycles.
Technique
Inject bacteriostatic water slowly down the side of the vial. Do not shake — gently swirl until fully dissolved. Solution should be clear and colorless.
Notes
Benzyl alcohol in bacteriostatic water acts as a preservative, extending usable life of reconstituted peptide. Sterile water may be used but limits shelf life to 24–48 hours.
Research Dosing Reference
The following dosing information is derived from published clinical and preclinical research literature and is provided for reference purposes only. It does not constitute medical advice.
Clinical / Human Research Range
Clinical trials used 0.25 mg/week escalating to 2.4 mg/week (STEP trials). Subcutaneous administration in human subjects.
Preclinical Models
Rodent studies: 0.03–0.3 mg/kg subcutaneous. Primate studies: 0.01–0.1 mg/kg.
Calculation Example
For a 2.5 mg/mL solution: a 0.5 mg research dose = 0.2 mL (200 mcg/mL × 0.2 mL). Use an insulin syringe for precision.